Business Wire

MA-VERACODE

29.5.2024 14:31:31 CEST | Business Wire | Press release

Share
Veracode Research Reveals Government Applications at Heightened Risk of Cyber Attack: 59% Have Flaws Left Unfixed for More than a Year

Veracode, a global leader in application risk management, today released research revealing applications developed by public sector organizations have more security debt than those created by the private sector. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 59 percent of applications in the public sector, compared to the overall rate of 42 percent. The research analyzed public sector organizations in more than 25 countries across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529282258/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 2: Security Debt in Public Sector Applications (Graphic: Business Wire)

“Decades of accumulated security debt in unpatched software and poor security configurations, are in the applications that serve our government,” said Chris Eng, Chief Research Officer at Veracode. “Without a systematic and continuous approach to finding and fixing security flaws, the public sector is left dangerously exposed to attacks from hackers.”

Federal government systems are increasingly under cyberattack, as malicious criminals target public sector organizations with more damaging and disruptive techniques. In response, the federal government is enforcing a flurry of initiatives to strengthen cybersecurity, including efforts to reduce risk in the applications that serve the government. In March of 2024, the Cybersecurity and Infrastructure Security Agency (CISA) and the Office of Management and Budget (OMB) released the Secure Software Development Attestation Form to hold providers to the federal government accountable for insecure software.

Veracode researchers found that while slightly fewer public sector organizations (68 percent) have security debt than other industries (71 percent), they tend to accumulate more of it. Only three percent of applications are flaw-free, compared to six percent across other industries. Even more concerning, 40 percent of public sector entities have persistent, high-severity flaws that constitute ‘critical’ security debt, which would put the confidentiality, integrity, and availability of businesses at serious risk if exploited.

“The good news is that most organizations have the capacity to remediate all critical debt, but risk prioritization is key,” said Eng. “Two-thirds of all flaws in public sector organizations are either less than one year old or are not critical in severity. In addition, less than one percent of all flaws constitute critical security debt. By prioritizing that security debt with focused effort, organizations can achieve maximum risk reduction and then move to address non-critical flaws based on their risk tolerance and capabilities.”

According to the report, security debt in the public sector primarily affects first-party code (93 percent), but most of the critical security debt comes from third-party dependencies (55.5 percent). This reinforces the importance of the Open Source Security Software Initiative (OS3I), an inter-agency working group focused on ensuring open-source software is “as safe, secure and sustainable as it is open.” It also emphasizes the need for organizations to focus on both first- and third-party code to effectively reduce security debt.

The analysis further shows security debt in the public sector is primarily concentrated in older, larger applications (22 percent). This is especially true for critical security debt (30 percent), confirming a correlation between application age and the accumulation of security debt. Researchers also compared the security debt profile for different development languages and found that Java and .NET applications stand out as significant sources of debt in the public sector.

“The current state of software security in the public sector reinforces the importance of making secure by design a standard approach for the whole network connected world,” closed Eng. “We applaud CISA’s recent announcement of its Secure by Design Pledge and are proud to be one of the inaugural signatories. Our goal with this research is to further support our government and industry partners in promoting widespread adoption of these principles.”

The full State of Software Security Public Sector 2024 report is available to download on the Veracode website.

About the State of Software Security Report

The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529282258/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye